Janssen Claims Preemption In $4M Topamax Defect Appeal
Janssen Pharmaceuticals Inc. urged a Pennsylvania appeals court Monday to overturn a $4 million jury verdict on the grounds that federal preemption barred state-law claims that the company failed to warn...To view the full article, register now.
Already a subscriber? Click here to view full article